Home / GLP-1 appeals / Denial reasons / Off-label for weight loss
Denial reason · Off-label for weight loss
Your GLP-1 was denied as off-label for weight loss. Here is how to appeal it.
Ozempic and Mounjaro are FDA-approved for type 2 diabetes, not weight loss, so plans often deny them for weight. The path forward is usually one of two: document an approved indication you actually have, or move to the on-label weight-management product. We draft it for free, grounded in your plan's own rules with every citation verified. You review, sign, and file it.
Free to draft. Every citation checked against your plan's policy and the FDA label before you file.
Why it happens
Indication mismatch
Ozempic and Mounjaro are approved for type 2 diabetes; a weight-loss claim falls outside the label.
Two common paths
On-label or approved use
Switch to Wegovy or Zepbound for weight, or document a covered indication you have.
Your deadline
Often 60 to 180 days
For your plan's first internal appeal. Your denial notice states the exact window, check it.
What an off-label-for-weight-loss denial means
The FDA approves each drug for specific uses, and a plan's coverage usually tracks those approved indications. Ozempic (semaglutide) and Mounjaro (tirzepatide) are FDA-approved for type 2 diabetes. They are not FDA-approved for weight loss. So when one of them is prescribed and billed for weight management, many plans deny it as off-label, even though the same molecules are approved for weight in separate products. This is one of the most common and most fixable GLP-1 denials. The patterns:
- The claim is coded for weight loss on a diabetes drug. If Ozempic or Mounjaro is submitted for weight management, the plan reads it as outside the FDA label and denies it on that basis.
- A diagnosis exists but was not documented. Many people prescribed these drugs do have type 2 diabetes or another covered condition, but the records submitted did not show it. The denial is about documentation, not eligibility.
- The on-label option fits better. For weight management specifically, the FDA has approved Wegovy (semaglutide) and Zepbound (tirzepatide), the same molecules as Ozempic and Mounjaro. If weight is the goal, switching the request to the on-label product can change the coverage analysis entirely.
- Even the on-label drug can be denied separately. Wegovy and Zepbound are FDA-approved for weight, but plans may still apply weight-loss exclusions, BMI criteria, or step therapy. That is a different denial with its own appeal path.
How to win an off-label appeal
The winning move depends on your situation, and the honest first step is figuring out which one you are in.
The move: if you have type 2 diabetes or another indication the drug is approved for, document it clearly and appeal on the approved use. If weight management is the real goal, the cleaner path is often to request the FDA-approved weight product, Wegovy or Zepbound, rather than fighting to use a diabetes drug off-label. We help you see which path your denial actually supports.
- Confirm your indication. If you have type 2 diabetes, document the diagnosis and relevant labs so the claim sits squarely inside the FDA-approved use for Ozempic or Mounjaro.
- Consider the on-label switch. For weight management, Wegovy and Zepbound are the FDA-approved options. Moving the request to the on-label product can sidestep the off-label objection. Whether to switch is a clinical decision for you and your prescriber.
- Cite the FDA label and your records together. Whatever path fits, ground the appeal in the prescribing information and the documentation that supports the approved indication. The clinical opinion comes from your clinician, not from us.
- File within the window, then escalate. Under the Affordable Care Act you have the right to a full internal appeal and, if upheld, an independent external review by a reviewer not employed by your plan.
Sources include your plan's published coverage policy and the FDA prescribing information for each medication, which defines the approved indications. We cite the specific policy that applies to your plan when we build your appeal.
The magic is visible
Your appeal, built from the FDA label and your plan's rules. Every citation checked.
We draft from the sources below, then verify each one before you file. On our held-out testing: 0 invented citations, versus about 1 in 4 for raw AI.
Sample appeal, built from real source types
- FDA labelThe approved indications for Ozempic, Mounjaro, Wegovy, and ZepboundVerified
- Your plan's coverage policyYour plan's published rules for GLP-1 coverage by indicationVerified
- Your recordsYour diagnosis and clinical history supporting an approved indication, cited back accuratelyVerified
Let's check your off-label denial, free.
Answer a few questions for an honest read on your odds, then your verified draft. No account, no cost.
Check my denial, free